ALZN
Alzamend Neuro, Inc.NASDAQHealthcare$1.00-1.97%ClosedMarket Cap: $3.1M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
1.65
P/S
0.00
EV/EBITDA
-0.04
DCF Value
$7.42
FCF Yield
-206.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-177.5%
ROA
-174.2%
ROIC
-322.0%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q3 2026 | $0.00 | -Infinity% | $-2.2M | $-2.2M | $-0.58 | — |
| Q2 2026 | $0.00 | -Infinity% | $-998.1K | $-1.0M | $-0.30 | — |
| Q1 2026 | $0.00 | -Infinity% | $-2.7M | $-2.7M | $-1.28 | — |
| Q4 2025 | $0.00 | -Infinity% | $-1.1M | $-1.1M | $-2.43 | — |
| FY 2025 | $0.00 | -Infinity% | $-4.5M | $-4.5M | $-11.32 | — |
| Q3 2025 | $0.00 | -Infinity% | $-1.0M | $-1.0M | $-1.70 | — |
| Q2 2025 | $0.00 | -Infinity% | $-1.4M | $-1.4M | $-3.61 | — |
| Q1 2025 | $0.00 | -Infinity% | $-962.0K | $-974.0K | $-11.42 | — |
| Q4 2024 | $76.1K | -16.7% | $-850.1K | $-851.5K | $-11.14 | — |
| FY 2024 | $0.00 | -Infinity% | $-9.9M | $-9.9M | $-132.33 | — |
| Q3 2024 | $0.00 | -Infinity% | $-2.7M | $-2.7M | $-33.97 | — |
| Q2 2024 | $0.00 | -Infinity% | $-2.9M | $-2.9M | $-39.85 | — |